Swedencare’s Q3 growth leans on pharma and dental as US lags
Bottom line
Swedencare reported third-quarter 2026 revenue of SEK 732.2 million, up 3% year over year, as strong performance in dental, pharma, Europe, and production helped offset continued weakness in North America and softer nutraceutical sales. The company said organic, currency-adjusted growth was 2%, while operational EBITDA slipped 3% to SEK 150.1 million. Management highlighted especially strong momentum in dental brand ProDen PlaqueOff and in its pharma operations, including an FDA pre-approval inspection clearance for its North American Rx facility. Swedencare also said it consolidated Belgian pet health company Viyo from July 1 after increasing its stake, and confirmed that CEO Håkan Lagerberg plans to step down during 2027 after a transition period. (investegate.co.uk)
Why it matters: For veterinary professionals, the quarter shows where animal health demand is holding up and where it's not. Swedencare said the U.S. veterinary channel remains weak, but it expects larger partnerships and product launches in early 2027 to help improve performance. At the same time, growth in dental and pharma suggests clinics and pet parents are still spending in categories tied to everyday preventive care, recovery, and prescription-adjacent support, even as broader supplement demand looks less consistent. (investegate.co.uk)
What to watch: Watch whether Swedencare can stabilize North America, convert its pharma pipeline into 2027 launches, and execute its CEO transition without disrupting strategy after lowering its full-year growth ambition to about 6% organic growth. (investegate.co.uk)
Swedencare's third quarter offered a mixed picture: enough growth in pharma, dental, Europe, and production to keep revenue moving higher, but not enough to fully overcome persistent weakness in the U.S. business. The Swedish pet health group posted Q3 revenue of SEK 732.2 million, up 3% from a year earlier, while organic, currency-adjusted growth came in at 2%. Operational EBITDA fell 3% to SEK 150.1 million, and management acknowledged that North America remains the company's main operational problem. (investegate.co.uk)
That tension has been building for some time. In September 2026, Swedencare announced that CEO Håkan Lagerberg intended to step down after a 12-month notice period, ending a 12-year run in which he helped build the company from a small single-product business into a global animal health group. In the Q3 report and earnings call, Lagerberg tied the timing partly to a disappointing growth year, while stressing that he expects the incoming CEO to inherit a business on firmer footing. (mfn.se)
The quarter's strongest areas were clear. On the earnings call, management said Europe and the production segment each delivered 11% organic growth, while dental and pharma "continued to perform really strongly." ProDen PlaqueOff posted growth above 30% overall, including 33% organic growth in North America, with management pointing to strength across online, pet retail, and veterinary channels. In pharma, Swedencare said Summit Vet continued double-digit growth in the U.K. and launched what it described as the first pharmaceutical special soft chew on the U.K. market. The company also said its Vetio North Rx facility in North America passed a U.S. FDA pre-approval inspection with no observations, supporting planned production starts in 2027. (stockanalysis.com)
The drag came from elsewhere, especially the U.S. veterinary channel and parts of the NaturVet business. Swedencare said North America remains challenging, and that the veterinary channel is still soft. Management said larger partnerships and scheduled launches in early 2027 should help, but also cautioned that any recovery will be gradual rather than immediate. The company further signaled a reset in expectations, saying double-digit organic growth for full-year 2026 is no longer a probable outcome and that it now expects around 6% organic growth for the year. Market coverage following the report focused on that miss versus expectations and on the continued North American weakness. (investegate.co.uk)
Swedencare also used the quarter to deepen its position in Viyo, a Belgian company focused on palatable liquid health products for cats and dogs. Management said Viyo was consolidated from July 1 after Swedencare moved to a majority holding. The business adds immune-support and recovery-oriented products that appear complementary to Swedencare's broader veterinary and supplement portfolio. Viyo describes itself as a Belgian developer of liquid health solutions, including products aimed at immunity and recuperation support. (stockanalysis.com)
Industry reaction was measured rather than celebratory. Investor-oriented coverage emphasized that revenue and EBITDA came in below analyst expectations and that investors appeared more concerned about the organic growth slowdown than encouraged by the quarter's record sales level. That's not a veterinary market readout on its own, but it does underscore how much confidence now depends on whether Swedencare can restore momentum in North America while proving that its faster-growing pharma and dental segments can scale. (investing.com)
Why it matters: For veterinary professionals, the quarter is a useful snapshot of where demand in companion animal health may be proving more resilient. Dental products, recovery support, and pharmaceutical manufacturing tied to approved or clinic-facing products appear to be holding up better than some broader nutraceutical lines. Swedencare's comments also reinforce that the U.S. veterinary channel remains uneven, even for established pet health companies, which may matter for distributors, clinic buyers, and manufacturers watching category performance into 2027. The FDA-related progress in pharma is also notable because it suggests Swedencare is trying to lean harder into regulated, harder-to-replicate product areas rather than relying only on wellness supplements. (investegate.co.uk)
What to watch: The next markers are whether North America returns to positive growth in late 2026 or early 2027, whether planned U.S. partnerships and launches actually lift the veterinary channel, how quickly Viyo is integrated across Swedencare's platform, and whether the CEO succession process changes capital allocation or category priorities. Swedencare's own guidance suggests 2027, not the current quarter, is the real test of whether this portfolio mix can translate into broader recovery. (stockanalysis.com)